Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Stoke Therapeutics Inc
(NQ:
STOK
)
11.60
-0.34 (-2.85%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Stoke Therapeutics Inc
< Previous
1
2
Next >
Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference
February 07, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023
January 09, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting
December 02, 2022
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting
November 29, 2022
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
November 14, 2022
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet Syndrome
November 10, 2022
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)
August 25, 2022
From
Stoke Therapeutics
Via
Business Wire
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
August 08, 2022
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference
June 01, 2022
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 10, 2022
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002
May 02, 2022
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
April 07, 2022
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
April 05, 2022
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Participate in the Cowen 42nd Annual Health Care Conference
February 28, 2022
From
Stoke Therapeutics, Inc.
Via
Business Wire
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
January 10, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Stoke Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting
December 03, 2021
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Announces Presentations from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting
November 19, 2021
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
November 08, 2021
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at Upcoming Investor Conferences in November
November 03, 2021
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at the Cantor Global Healthcare Virtual Conference
September 22, 2021
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome
September 21, 2021
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
August 10, 2021
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at Upcoming Investor Conferences in August
August 03, 2021
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at the UBS Global Healthcare Virtual Conference
May 18, 2021
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 10, 2021
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy (ADOA)
May 04, 2021
From
Stoke Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.